Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
ARA-290 vs Thymosin α-1
An educational, source-based comparison of ARA-290 and Thymosin α-1 — how each peptide works, what it's researched for, and what to know before going deeper.
Erythropoietin-derived peptide researched for neuropathy and tissue repair.
A synthetic 11-amino-acid peptide derived from the erythropoietin molecule. Research indicates it retains the tissue-protective (non-erythropoietic) effects of EPO via the β-common receptor, without stimulating red blood cell production.
- Small-fiber neuropathy and sarcoidosis
- Diabetic neuropathy
- Ischemia-reperfusion injury
- Autoimmune modulation
- • Investigational; not FDA-approved.
- • Does not raise hematocrit like full EPO molecule.
A 28-amino-acid peptide naturally produced by the thymus. Research indicates it modulates T-cell maturation, dendritic cell function, and innate immune signaling. Approved in several countries (under the name Zadaxin) as an adjunct in hepatitis B/C and certain cancer protocols.
- Chronic viral hepatitis (approved use abroad)
- Vaccine response augmentation
- Immunosenescence
- Adjunct in oncology research
- • Approved in 35+ countries but not FDA-approved in the US.
- • Generally well tolerated in published clinical data.
- • Requires physician oversight.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| ARA-290 | ARA-290 in sarcoidosis-associated small-fiber neuropathy | Neurology | 2018 | Improved pain scores and corneal nerve fiber density in sarcoidosis patients. |
| ARA-290 | ARA-290 tissue protective effects | British Journal of Pharmacology | 2015 | Reviewed non-hematopoietic protective mechanisms via the innate repair receptor. |
| Thymosin α-1 | Thymosin alpha 1: a comprehensive review of clinical experience | Annals of the New York Academy of Sciences | 2010 | Reviews approved uses and ongoing trials across viral, oncologic, and immune indications. |
Side-effect & safety grid
- Investigational; not FDA-approved.
- Does not raise hematocrit like full EPO molecule.
- Approved in 35+ countries but not FDA-approved in the US.
- Generally well tolerated in published clinical data.
- Requires physician oversight.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
ARA-290 vs Thymosin α-1 — Key differences
- Class: ARA-290 is classified as Neuropathic · Immune Modulation, while Thymosin α-1 is Immune Modulation.
- Primary research focus: ARA-290 — small-fiber neuropathy and sarcoidosis; Thymosin α-1 — chronic viral hepatitis (approved use abroad).
- Tag: Neuropathic pain · Immune vs Immune.